Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Address: Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany. Electronic address: [email protected].; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany.; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Oncology Institute of Southern Switzerland, EOC, Medical Oncology, Bellinzona, Switzerland.; 3rd Medical Department, Paracelcus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria.; Prince of Wales Hospital Department of Haematology and University NSW, Sydney, NSW, Australia; Australasian Leukaemia & Lymphoma Group, Melbourne, VIC, Australia.; University of Tübingen, Tübingen, Germany.; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany.; Department of Haematology, Hanusch Krankenhaus, Vienna, Austria.; University Hospital Hamburg-Eppendorf, Hamburg, Germany.; Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany.; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Department of Medical Oncology, University Hospital Bern, Bern, Switzerland.; Department of Hematology and Oncology, University of Heidelberg, Heidelberg, Germany.; Department of Hematology and Oncology, Klinikum Leverkusen, Leverkusen, Germany.; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Berlin, Germany; Humboldt University of Berlin, Berlin Institute of Health, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, Berlin, Germany; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany.; Department of Hematology, Amsterdam UMC, Vrije Universiteit, Cancer Center, Amsterdam, Netherlands.; Department of Oncology, Oslo University Hospital, Oslo, Norway; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany.; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.; Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.; Department of Haematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany.; Department of Haematology and Bone Marrow Transplant, Royal-Adelaide-Hospital, Adelaide, SA, Australia.; Klinik für Innere Medizin II, Jena University Hospital, Jena, Germany.; Department of Internal Medicine II, Hematology and Oncology, University Hospital Wuerzburg, Wuerzburg, Germany.; Department of Haematology and Oncology, Göttingen, Germany.; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Germany.; Department of Medicine III, Universitätsmedizin Mainz, Mainz, Germany.; Department for Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, Muenster, Germany.; Hämatologie, Onkologie und Tumorimmunologie, HELIOS Klinikum Berlin-Buch, Berlin, Germany.; Department of Internal Medicine II, University Hospital Augsburg, Augsburg, Germany.; Department of Hematology and Oncology, Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, Germany.; Clinic for Hematology, Oncology, Immunology and Palliative Medicine, Vincentius-Deaconry Clinics gAG, Karslruhe, Germany.; Clinic for Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany.; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany; Department of Hematology, University Hospital of Aarhus, Aarhus, Denmark.; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden.; Ordensklinikum Linz Elisabethinen, Linz, Austria.; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany.; Institute for Pathology, University Hospital Würzburg, Würzburg, Germany.; Karl Lennert Cancer Center, University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany.; Department of Radiation Oncology, University Hospital of Ruhr-Universität Bochum, Marien Hospital Herne, Herne, Germany.; Global Medical Lead for Lymphoma & Leukemia at Takeda Oncology, Cambridge, MA, USA.; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany.; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Cologne, Germany.